Shots:

• Novartis sells a part of Sandoz US- which includes ~300 products that generated $0.6B in H1’18
• This transaction includes development projects along with ~300 products to Aurobindo Pharma USA Inc. for $0.9B in cash & $0.1B of potential earn-outs- with expected closure in 2019
• Aurobindo will also take over manufacturing facilities in Wilson- North Carolina- Hicksville- Melville- New York
• This transaction includes transfer of ~750 employees in Hicksville- Melville- Wilson and Princeton- New Jersey including PharmaDerm representatives to be transferred to Aurobindo
• The focus is to support Sandoz on complex generics- value added medicines and biosimilar in achieving continued and profitable growth in US for long term

   Ref: Novartis | Image: Novartis